Literature DB >> 10786814

Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases.

P J Zhang1, M Barcos, C C Stewart, A W Block, S Sait, J J Brooks.   

Abstract

MIC2 is characteristically expressed in lymphoblastic lesions and Ewing's/primitive neuroectodermal tumor sarcomas. Although MIC2 has recently been reported in chloroma and rare terminal deoxynucleotidyl transferase-positive acute myelogenous leukemia (AML), the incidence and the significance of MIC2 (CD99) immunoreactivity in myeloid lesions is not clear. In this study, we evaluated MIC2 positivity in a variety of myeloid diseases and normal marrow to determine its incidence and distribution in myeloid diseases; its correlation with flow cytometric and cytogenetic data in AML; and its association with leukemic transformation, relapse, and chloroma formation. Paraffin sections of 11 chloromas and 94 bone marrow core biopsies from 66 patients were stained with CD99 monoclonal antibody 12E7. Of 94 bone marrow core biopsies, there were 30 AML (fragment antigen binding M0 to M6), 23 remissions, 5 relapses, 12 myeloproliferative disorders, 13 myelodysplastic syndromes, and 11 normal marrows from patients who did not have leukemia. CD99 immunoreactivity was evaluated with light microscopy. MIC2 expression was seen in leukemic blasts in 6 of 11 chloromas (55%) and 13 of 30 AML (43%) but rarely in myeloproliferative disorders, myelodysplastic syndromes, remission, and normal marrow. CD99 tended to be positive in M1-, M3-, and HLA-Dr-negative AML and negative in AML with relapse. MIC2 expression did not correlate with the karyotype independent of French-American-British Cooperative Group classification and the disease remission or occurrence of chloroma in AML. We concluded that MIC2 is commonly expressed in leukemic blasts of AML and is not predictive of leukemic transformation from myeloproliferative disorders and myelodysplastic syndromes or chloroma formation. Caution should be taken when using MIC2 as a marker for Ewing's sarcoma/ primitive neuroectodermal tumor or lymphoblastic lymphoma on paraffin sections of either soft tissue or bone marrow specimens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10786814     DOI: 10.1038/modpathol.3880077

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  11 in total

Review 1.  Granulocytic sarcoma of the spine in a child without bone marrow involvement: a case report and literature review.

Authors:  Yusuke Shiozawa; Nobutaka Kiyokawa; Masahiro Saito; Junichiro Fujimoto; Jun-Ichi Hata; Yuichiro Yamashiro
Journal:  Eur J Pediatr       Date:  2005-07-13       Impact factor: 3.183

Review 2.  Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosis.

Authors:  Marcus Kremer; Leticia Quintanilla-Martínez; Jörg Nährig; Christoph von Schilling; Falko Fend
Journal:  Virchows Arch       Date:  2005-10-18       Impact factor: 4.064

Review 3.  CD99 in malignant hematopoiesis.

Authors:  Atham Ali; Vijaya Pooja Vaikari; Houda Alachkar
Journal:  Exp Hematol       Date:  2021-12-14       Impact factor: 3.249

4.  Immunoreactivity of CD99 in non-Hodgkin's lymphoma: unexpected frequent expression in ALK-positive anaplastic large cell lymphoma.

Authors:  Chang Ohk Sung; Young H Ko; Sanghui Park; Kihyun Kim; Wonseog Kim
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

5.  Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia.

Authors:  Vijaya Pooja Vaikari; Mincheol Park; Lena Keossayan; J Andrew MacKay; Houda Alachkar
Journal:  Nanomedicine       Date:  2020-06-12       Impact factor: 5.307

6.  Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.

Authors:  Donald D Rao; Christopher Jay; Zhaohui Wang; Xiuquan Luo; Padmasini Kumar; Hilary Eysenbach; Maurizio Ghisoli; Neil Senzer; John Nemunaitis
Journal:  Mol Ther       Date:  2016-05-11       Impact factor: 11.454

Review 7.  CD99: A Cell Surface Protein with an Oncojanus Role in Tumors.

Authors:  Maria Cristina Manara; Michela Pasello; Katia Scotlandi
Journal:  Genes (Basel)       Date:  2018-03-13       Impact factor: 4.096

8.  Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases.

Authors:  Su-Jin Shin; Hyangsin Lee; Geunyoung Jung; Minchan Gil; Hosub Park; Young Soo Park; Dok Hyun Yoon; Cheolwon Suh; Chan-Jeoung Park; Jooryung Huh; Chan-Sik Park
Journal:  Korean J Pathol       Date:  2014-06-26

9.  MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.

Authors:  Zhihong Zeng; Rui-Yu Wang; Yi Hua Qiu; Duncan H Mak; Kevin Coombes; Suk Young Yoo; Qi Zhang; Katti Jessen; Yi Liu; Christian Rommel; David A Fruman; Hagop M Kantarjian; Steven M Kornblau; Michael Andreeff; Marina Konopleva
Journal:  Oncotarget       Date:  2016-08-23

10.  Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia.

Authors:  Vijaya Pooja Vaikari; Yang Du; Sharon Wu; Tian Zhang; Klaus Metzeler; Aarif M N Batcha; Tobias Herold; Wolfgang Hiddemann; Mojtaba Akhtari; Houda Alachkar
Journal:  Haematologica       Date:  2019-08-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.